Chimerix’s (CMRX) Outperform Rating Reiterated at Wedbush

Chimerix (NASDAQ:CMRX)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research note issued to investors on Thursday,RTT News reports. They currently have a $6.00 price objective on the biopharmaceutical company’s stock.

CMRX has been the subject of a number of other reports. StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Chimerix in a research note on Wednesday, August 14th.

Chimerix Price Performance

Shares of CMRX stock traded down $0.07 on Thursday, reaching $0.94. 385,299 shares of the company were exchanged, compared to its average volume of 352,250. The company has a 50-day moving average of $0.90 and a 200-day moving average of $0.91. Chimerix has a one year low of $0.75 and a one year high of $1.30. The company has a market cap of $83.82 million, a price-to-earnings ratio of -0.98 and a beta of 1.13.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.23). The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $1.26 million. During the same quarter in the prior year, the business earned ($0.21) earnings per share. As a group, sell-side analysts predict that Chimerix will post -0.91 EPS for the current year.

Institutional Investors Weigh In On Chimerix

Institutional investors have recently added to or reduced their stakes in the business. Koshinski Asset Management Inc. purchased a new stake in Chimerix in the 1st quarter worth approximately $42,000. Valeo Financial Advisors LLC raised its stake in shares of Chimerix by 566.9% during the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 69,505 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Chimerix in the 2nd quarter valued at $137,000. Finally, Acadian Asset Management LLC grew its holdings in shares of Chimerix by 15.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after purchasing an additional 291,981 shares during the last quarter. 45.42% of the stock is owned by hedge funds and other institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.